The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...
The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback